Hepatitis C Draft Guidance Cites Utility Of Unapproved HCV-RNA Tests
This article was originally published in The Gray Sheet
Clinical trials of hybridization assays for monitoring hepatitis C viral RNA may use other unapproved HCV-RNA assays to corroborate test results, provided supporting data is submitted, FDA indicates in a recently released draft guidance.
You may also be interested in...
HEPATITIS C RNA PANEL SHOULD BE DEVELOPED TO TEST NEW ASSAYS, PANEL SAYS; DCLD DEVELOPING GUIDANCE ON VARIOUS HEPATITIS A, B, C TESTS AND INDICATIONS
FDA should develop a panel of hepatitis C virus RNA specimens to challenge new qualitative HCV RNA assays, the agency's Microbiology Devices Panel recommended at its Feb. 12 meeting in Gaithersburg, Maryland. The group was convened to assist FDA's Center for Devices and Radiological Health in efforts to develop a guidance that will prescribe clinical study guidelines for hepatitis A, B, or C tests for diagnosis and/or monitoring indications.
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.